News
15 Apr 2021
RHEUMATOLOGY
Osteoarthritis
TRB Chemedica researches, develops, manufactures and markets different molecules to treat osteoarthritis-induced pain such as hyaluronic acid-based products and diacerein. OSTENIL® range consists of sodium hyaluronate-containing products with different formulations and has been developed to improve osteoarthritis patients’ symptoms and joint function after intra-articular injection.
Osteoarthritis is classified as the most prevalent joint disorder, especially in middle-aged and elderly people, and is therefore seen as one of the ten most disabling diseases in developed countries.
Mentioned Companies
TRB Chemedica International SA
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance